Abstract
This case highlights the importance of vigilance for both thrombotic and inflammatory adverse events in patients with common variable immunodeficiency who are receiving intravenous immunoglobulin. It demonstrates that a multifaceted approach, including altering the product, infusion rate, and premedication, can effectively manage these complex complications.